Evaluation of efficacy and safety of pregabalin and carbamazepine in reducing pain

Evaluation of the efficacy and safety of pregabalin and carbamazepine in patients with postherpetic neuralgia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210725051977N1

Enrollment

Registered

2021-11-12

Start date

2021-10-11

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evaluation of the efficacy and safety of pregabalin and carbamazepine in patients with postherpetic neuralgia. Zoster with other nervous system involvement

Interventions

Intervention 1: Intervention group: Oral carbazampine treatment group with a daily dose of 400 mg, for 8 weeks. Intervention 2: Intervention group: Oral Pregabalin treatment group with a daily dose of

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age older than 18 History of postherpetic neuralgia for at least 1 month

Exclusion criteria

Exclusion criteria: History of Allergy to carbamazepine or pregabaline History of kidney or liver disease

Design outcomes

Primary

Measure	Time frame
Severity of post-herpetic neuralgia in each group. Timepoint: 2, 5 and 8 weeks after starting the treatment. Method of measurement: visual analogue scale.	—

Secondary

Measure	Time frame
Frequency of adverse drug complications in each group. Timepoint: 2, 5 and 8 weeks after starting the drug, or as soon as warning complications occurred. Method of measurement: check list including possible adverse drug reactions following carbamazepine or pregabalin.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Masoud Khoshbin

Islamic Azad University

masoudkhoshbin@iauyazd.ac.ir+98 35 3138 0155

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026